Weedie


Home / Newswire

v1.0.0
Home
Stocks
Warrants
Heatmap
Newswire
Shorts
Halts
Licenses

Weedstocks Newswire Feed

Weedstocks news RSS feed

Canntab Advances its Revenue Model with Recent Sales License Approval for FSD Pharma from Health Canada

2019-04-23 08:00:30

- Opens the Door for Canadian and International Sales and White Labeling -

TORONTO, April 23, 2019 /CNW/ - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") is pleased to announce that by virtue of FSD Pharma Inc. ("FSD"), with whom Canntab has entered into a collaboration and profit sharing agreement, being granted a "sale for medical purposes" licence by Health Canada pursuant to the Cannabis Act and Cannabis Regulations (the "FSD Licence"), Canntab is close to being in a position to sell its products and generate revenue. The FSD Licence allows Canntab to produce samples of capsules containing CBD and/or THC, which, if approved by Health Canada, will enable Canntab to launch production and sales out of its manufacturing facility located in Room 6 of FSD's Health Canada approved facility in Cobourg, Ontario. In addition, the FSD Licence, when combined with an export permit, which FSD intends to acquire as soon as possible, may also allow Canntab to sell its products in foreign markets.

Jeffrey Renwick, Chief Executive Officer of Canntab, stated "We are thrilled that FSD has received its sales licence from Health Canada, and want to congratulate the entire FSD team on this significant milestone! Once we receive Health Canada approval for our capsules, we will begin white labeling for Canadian licensed producers, including FSD Pharma. Once FSD is able to export, Canntab will be able to sell its proposed products in foreign jurisdictions, including Australia and Mexico where we have agreements in place. We look forward to continuing to work closely with the team at FSD during this exciting new phase of our businesses."

About Canntab

Canntab Therapeutics is a Canadian cannabis oral dosage formulation company based in Markham, Ont., engaged in the research and development of advanced pharmaceutical-grade formulations of cannabinoids. Canntab has developed patent-pending technology to deliver standardized medical cannabis extract from selective strains in a variety of extended-release/sustained-release pharmaceutical dosages for therapeutic use. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Canntab's primary focus is on providing cannabis-based products to medical professionals that can be used to deliver therapeutic treatments to their patients. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB Venture Market under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

...

Read more


Revolutionizing Breakthrough for those suffering from chronic pain: a clinical research with medical cannabis sublingual tablets is currently on its way

2019-04-23 08:00:05

Panaxia in collaboration with Rafa, the Israeli Pharmaceutical company, has begun a clinical trial for registration at the Ministry of Health, intended to make medical cannabis accessible to a wide range of patients asking to receive the treatment in a conventional pharmaceutical way other than smoking, in order to ensure an accurate and consistent treatment dosage.

LOD, Israel, April 23, 2019 /CNW/ -- The pharmaceutical company Panaxia Israel Pharmaceutical Industries, announced a clinical trial for registration purposes at the Ministry of Health, a first of its kind process, for delivering sublingual tablets of medical cannabis to examine their bioavailability and safe consumption. Panaxia's medical cannabis products, distributed by the pharmaceutical company Rafa, are being tested as part of a clinical trial, and their registration following the trial will revolutionize medical cannabis treatment. The greatest potential in tablets which are taken sublingually, is mainly for patients suffering from chronic/persistent pain.

As of November 2018, chronic neuropathic pain is considered the most common medical condition in over 42,000 patients with permits for medical cannabis treatment. "In extended chronic pain, there is a significant advantage for treatments with a relatively immediate response and a longer effect period," says Dr. Silviu Brill, Director of the Chronic and Acute Pain Center, at the Tel-Aviv Sourasky Medical Center, and Honorary Treasurer at the European Pain Federation. "This is why, medical cannabis sublingual tablets, which are based on clinical trials, are so significant in treating patients suffering from chronic pain. Tablets are a convenient, simple and familiar method of treatment administration for patients suffering from chronic pains, and will enable us physicians to better manage the treatment of pain with medical cannabis."

Sublingual tablets are adapted for treating most patients. 80% of the adult population in Israel are non-smokers, which is why this is good news for many patients which are unwilling or unable to smoke.

According to Dr. Dadi Segal, Panaxia CEO, "The clinical trial is performed as part of the registration process of the new products which we are planning to launch in Israel, in collaboration with Rafa, this year. By making medical cannabis accessible through tablets, we strive to provide treatment with medical cannabis products for patients with a wide range of diseases, after completing the trial and registration, and subject to recommendation by a medical specialist. Firstly, the new method of administration will enable patients to receive the treatment with no smoking damages."

...

Read more


Geyser Brands Appoints London-Based Agency Brandeavour for Geyser and Subsidiaries' Brand Development

2019-04-23 08:00:00

Also provides an update on proposed acquisition of Solace Management Group Inc. and expected branding and distribution initiatives to follow.

VANCOUVER, April 23, 2019 /CNW/ - Geyser Brands Inc. (TSXV:GYSR) ("Geyser Brands" or the "Company") is pleased to announce that it has engaged Anthony Webb - brand expert and strategist, Founder and CEO of Brandeavour - as the Company's consultant of record for strategic branding and creative counsel. The services to be provided by Brandeavour will include overall brand direction for Geyser Brands and its subsidiaries, and commercializing new brands.  Brandeavour will work alongside GetFresh Ventures, Geyser Brands' strategic partner providing data-driven digital growth services, on developing new channels to market for Geyser Brands.

In addition to his work with some of the world's leading brands across luxury products, sports, music, entertainment, and business, Anthony Webb has consulted for international bodies, such as the Danish Embassy, the Barbados High Commission, Jamaican High Commission, and the Commonwealth Secretariat.

"The Geyser Brands team is thrilled to have Anthony on board and working to support our business and brand growth," comments Andreas Thatcher, CEO at Geyser Brands. "Anthony is an old friend and confidant, and his global experience with consumers across all industries - from luxury products and retail to sports and entertainment - gives him a perspective into consumer needs and preferences that are rivaled by few in the industry. Combined with the data-driven digital strategy frameworks supported by GetFresh Ventures, we are perfectly positioned to develop a compelling, highly differentiated, and consumer-focused approach to brand growth and development."

The Company is planning to establish legal North American, European Union, and Asian retail and direct-to-consumer distribution for its health, pet, cosmetics, and beverages brands. It will start with hemp-derived products in jurisdictions where CBD remains under scrutiny, and will seek to acquire consumer health and wellness brands that wish to move into the hemp and CBD markets at home and abroad. The Company is negotiating non-binding letters of intent with a number of U.S. brands seeking Canadian distribution, and is also negotiating joint ventures with entities in China and Japan for the commercialization of its hemp products. All agreements are subject to TSX approval.

...

Read more


CROPs 57,600 Square Foot Nevada Nursery Ready for Plants for CBD Farms

2019-04-23 08:00:00

VANCOUVER, British Columbia, April 23, 2019 /CNW/ -- CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today that it has completed the construction of its 57,600 square foot nursery in Nye County, Nevada.

It has been equipped with trays and LED lighting specially designed to enhance the growth of plant starts for the 2019 CBD farms licenced on the company's various properties in the state. This was a key project in order to maximize yield, reduce farming risk and costs for the 2019 planting season.

CROP continues to gauge interest and review potential off take relationships for the 2019 season for its CBD products.

The global medical cannabis market value is expected to reach a value of US$ 45.4 Billion by 2024, with a CAGR of 22.9% during 2019-2024, according to IMARC research. The firm's estimate for last year was that it would to reach US$ 13.4 Billion.

CROP CEO, Michael Yorke, stated: "The CROP family of companies and subsidiaries continues to build strategic infrastructure in key states where we are present. These are one time builds that will streamline harvests, reduce risks and costs as well as maximize yields for many years to come."

...

Read more


Shoppers Drug Mart launches ecommerce platform for medical cannabis in Alberta

2019-04-23 08:00:00

Medical Cannabis by Shoppers Drug Mart (shoppersdrugmart.ca/cannabis) allows patients to order directly from a trusted source, provides counselling, strain selection and support

BRAMPTON, ON, April 23, 2019 /CNW/ - Today, Shoppers Drug Mart expanded its online platform for the sale of medical cannabis to patients in Alberta, providing a single, trusted source for all their cannabis therapy needs. The site brings together Canada's current ecommerce model for medical cannabis, with the expert advice and counsel from trusted healthcare professionals.

"As trusted medication experts, pharmacists have an important role to play in the safe and informed use of medical cannabis. This launch in Alberta is a leap forward for those looking for professional oversight and trusted support in this area," said Jeff Leger, President, Shoppers Drug Mart. "Medical cannabis, like any prescribed medication, requires the same level of counsel from a healthcare professional.  As medical cannabis is increasingly prescribed to Canadians for its therapeutic benefits, our goal is to enhance the service and support that patients receive through this process."

First launched in Ontario in January 2019, www.shoppersdrugmart.ca/cannabis provides patients access to a number of products from Canadian licensed producers, shipped directly and discreetly to their doorstep.  Additionally, Shoppers Drug Mart provides support for patients through the Shoppers Cannabis Care Centre – a call center staffed by professionals who can provide counselling and support for patients. Under current regulations, pharmacists cannot dispense medical cannabis from a pharmacy.

Patients in Alberta can now bring their medical document (which is similar to a prescription) to a local Shoppers Drug Mart pharmacy where the pharmacist will review their medical history and any contraindications based on current medications. Then, specialized advisors from the Shoppers Cannabis Care Centre will contact patients and provide support with online registration and strain selection.

...

Read more


Lifestyle Delivery Systems Inc. Announces that CSPA Group, Inc. Received First Place Honors for Its CannaStrips™ Entry in Kushstock Festival's Edible Competition

2019-04-23 08:00:00

VANCOUVER, British Columbia, April 23, 2019 /CNW/ -- Lifestyle Delivery Systems Inc. (CSE: LDS), (OTCQX: LDSYF), (Frankfurt: LD6, WKN: A14XHT) ("LDS" or the "Company") is happy to announce that its wholly-owned subsidiary, CSPA Group, Inc.'s flagship product, CannaStrips™, won first place honors at Kushstock 7 "Best Edible" competition, which was held at Adelanto Stadium in Adelanto, California on Saturday, April 20, 2019.

The Company's CannaStrips™ THC was amongst 12 other contestants in the same edible category.  Products in the "best edible" category were given to 200 judges to sample over a few days.  This is the very first contest in which the Company has entered CannaStrips™ and the result was a first place win for CannaStrips™. CSPA Group set up its promotion booth at the Kushstock 7 4/20 event sharing the information about its CannaStrips™ and purchase locations with the event's attendees.

Casey Fenwick, President of LDS, stated, "CannaStrips™ is an extremely unique product.  I have watched the edible category grow over the past few years, and our strip checks all of the boxes that make a great edible. It tastes great, it works, and it is not only reasonably priced but priced better than any other edible/sublingual on the market."

The Company's CEO, Brad Eckenweiler, stated, "The CannaStrips™ win against a diverse array of edible products supports our position that the market is ready for a discreet, quick, dosage accurate, consistent, and repeatable cannabis experience in a smokeless delivery product. It was a great event for LDS, CSPA Group, Inc. and the CannaStrips™ product line."

The Company also wishes to remind its shareholders of the Annual General Meeting being held in Adelanto on April 25, 2019. For those shareholders unable to attend the meeting in person, the Company will provide a video recording of the meeting along with a video tour of the facility.

...

Read more


High Tide Records 234% Increase in 4/20 Weekend Sales

2019-04-23 07:00:30

/NOT FOR DISTRIBUTION TO NEWSWIRE SERVICES IN THE UNITED STATES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS./

CALGARY, April 23, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (CSE:HITI) (OTCQB:HTDEF) (FRA:2LY), an Alberta-based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced approximately $441,000 in systemwide gross revenues ("Sales") from April 19th to 21st, 2019, which is a 234% increase over the $132,000 reported for the same three-day period in 2018. This record result was generated from the Company's 13 Canna Cabana-branded stores including the two partnered Ontario locations in Hamilton and Sudbury that opened on April 20th, from its 13 Smoker's Corner locations across Canada, as well as from the Grasscity, Famous Brandz and Smoker's Corner e-commerce websites.

Sales on April 20th, known as 4/20 in the cannabis community, increased by 125% over the same day in 2018 and accounted for 60% of the weekend's total compared to 89% last year, which was earned more evenly in 2019 due to four Canna Cabana retail cannabis stores in Alberta and the recently acquired Grasscity e-commerce website all operating throughout the weekend. "It was incredible to make history by selling cannabis and accessories across Canada on the first 4/20 after the legalization of recreational cannabis for adult use", said Raj Grover, President and Chief Executive Officer of High Tide. "I couldn't be prouder of our employees, partners and other stakeholders for all helping to make this 4/20 weekend so fantastic, not only from a financial perspective but also for symbolic reasons," added Mr. Grover. Other notable achievements on 4/20 were Sales of $72,000 at Canna Cabana Hamilton, $43,000 at Canna Cabana Sudbury and $39,000 on Grasscity.com.

High Tide is currently assisting with the opening and operation of a third cannabis retail location on Yonge Street in Toronto, Ontario. In Alberta, 11 Canna Cabana retail stores are currently operating of which 10 are corporately-owned and one is a franchise, while the next 25 corporately-owned locations are under various stages of development and construction. The Company has 13 Smoker's Corner accessories shops across Alberta, British Columbia and Nova Scotia, of which five are corporately-owned and eight are franchises. In Saskatchewan, the Company is progressing through the necessary steps to complete two pending cannabis retail business acquisitions.

About High Tide Inc.

...

Read more


Village Farms International Announces that All Growing Area at Pure Sunfarms' Delta 3 Greenhouse Now in Production/Company to Host First Quarter 2019 Conference Call Friday, May 10, 2019 at 11:00 a.m. ET

2019-04-23 07:00:00

-- Pure Sunfarms Remains Firmly on Track to Achieve Run-Rate Annual Production of 75,000 Kilograms by Mid-2019 –

VANCOUVER, April 23, 2019 /CNW/ - Village Farms International, Inc. ("Village Farms" or the "Company") (TSX: VFF) (NASDAQ: VFF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has, on schedule, completed planting of Quadrants 1 and 4 of its 1.1 million square foot Delta 3 greenhouse operation in Delta, BC.  As a result, the entire 1.03 million square feet of growing area at the Delta 3 facility (composed of 16 individual grow rooms) is now in production.  Pure Sunfarms remains on track to achieve full run rate annual production of 75,000 kilograms at the Delta 3 greenhouse operation by mid-2019.

"With the support of Village Farms' decades of experience developing and ramping up large-scale growing operations, the Pure Sunfarms team continues to execute on plan," said Michael DeGiglio, Chief Executive Officer, Village Farms. "We have great confidence in the team's ability to replicate the success of the Delta 3 cannabis operation with the nearly identical 1.1 million square foot Delta 2 'sister' facility, which will double Pure Sunfarms' annual production to 150,000 kilograms and support its goal to be the high-quality, low-cost producer in Canada."

As previously announced, Pure Sunfarms is targeting to complete its first harvest at the Delta 2 facility by mid-2020 and achieve full run-rate production at the Delta 2 facility in the fourth quarter of 2020.  (All targeted production timelines for the Delta 2 facility are subject to the timing and receipt of requisite Health Canada licenses.)

...

Read more


SugarBud Receives Confirmation of Readiness Letter from Health Canada in Respect of Cannabis Cultivation Facility

2019-04-23 07:00:00

TSX-Venture Exchange: SUGR, SUGR.WT

CALGARY, April 23, 2019 /CNW/ - SugarBud Craft Growers Corp. ("SugarBud" or the "Company") is pleased to announce that it has received a Confirmation of Readiness Letter ("COR Letter") from Health Canada in respect of its cannabis cultivation facility in Stavely, Alberta (the "Facility"). The COR Letter requests SugarBud's affirmative response that it has met Health Canada's license application requirements. The "Confirmation of Readiness" stage is the final stage in the application process.

On March 6, 2019, SugarBud announced the submission of its Affirmation of Readiness and Video Evidence Package ("Evidence Package") to Health Canada. The Evidence Package was meant to demonstrate to Health Canada that the Facility is fully functional and compliant under the Cannabis Act and Regulations. Upon SugarBud's demonstration to Health Canada that its Facility is fully functional and compliant under the Cannabis Act and Regulations, the Company will be granted its cultivation license, at which point it will be permitted to cultivate cannabis.

Craig Kolochuk, President and Chief Executive Officer of SugarBud, stated: "Receiving our COR Letter is a major milestone for SugarBud in becoming a licensed producer of cannabis. We are currently in dialogue with Health Canada and promptly addressing any final questions and comments. We've submitted our Evidence Package and we are confident that our Facility is world class and compliant with the Cannabis Act and Regulations."

Phase 1 of the Facility is comprised of 29,800 total square feet of floorplate. SugarBud estimates that under a full development scenario with four layers of flowering canopy, Phase 1 of the Facility will have up to 37,000 square feet of flowering canopy. At a metric of approximately 50 grams per square foot of flowering canopy per crop, and five crops per year, this equates to up to an estimated 9,250,000 grams of dried cannabis flower production per year.

...

Read more


Liberty Health Sciences Announces Successful Launch of Whole Flower Smokable Products; Strategic Changes

2019-04-23 07:00:00

TORONTO, April 23, 2019 /CNW/ - Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high quality cannabis, is pleased to announce that it successfully launched sales of its whole flower smokeable products as well as its pre-rolled cannabis cigarette products this past weekend. Liberty is also pleased to announce that Mr. Jeff Chan, Liberty's Vice President, Finance will serve as interim Chief Financial Officer following the previously announced resignation of Mr. Rene Gulliver as Chief Financial Officer effective April 14, 2019.

Launch of Whole Flower Smokeable Products

On April 19, 2019, Liberty officially launched sales of its whole flower smokeable products and pre-rolled cannabis cigarettes in selected dispensaries across the state, under its Liberty Health Sciences house brand. This resulted in Liberty's highest grossing weekend in its operational history.

"Our sales results from our first weekend of flower sales went beyond expectations," said Victor Mancebo, Interim Chief Executive Officer of Liberty. "This justifies our investment into our massive Liberty 360 facility, in which we expect to continue to increase our production capability and thereby better serve all patients across Florida."

Strategic Changes

...

Read more